PureTech News

Press releases
Press Releases - 2023-11-17
Karuna
PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia
Continue
Press Releases - 2023-11-14
Seaport
PureTech's LYT-300 (Oral Allopregnanolone) Achieved Primary Endpoint in a Phase 2a Acute Anxiety Trial in Healthy Volunteers
Continue
Press Releases - 2023-10-17
Other
PureTech to Present at Two Upcoming Investor Conferences
Continue
Press Releases - 2023-10-11
Celea Therapeutics – Deupirfenidone (LYT-100)
PureTech Presents Data from LYT-100 (Deupirfenidone) Trial in Healthy Older Adults at CHEST Annual Meeting
Continue
Press Releases - 2023-10-04
Vedanta
PureTech Founded Entity Vedanta Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of VE202 for the Treatment of Ulcerative Colitis and Receives Fast Track Designation
Continue
Press Releases - 2023-09-28
Karuna
KarXT, invented at PureTech, submitted for FDA Approval in Schizophrenia
Continue
Press Releases - 2023-09-27
Other
PureTech Announces the Appointment of Robert Lyne as Chief Portfolio Officer
Continue
Press Releases - 2023-08-29
Other
Celea Therapeutics – Deupirfenidone (LYT-100)
PureTech Health plc - Half-Year Report
Continue
Press Releases - 2023-08-22
Other
Notice of Half-Yearly Results
Continue
Press Releases - 2023-08-01
Seaport
PureTech Awarded up to $11.4 Million from U.S. Department of Defense to Advance LYT-300 (Oral Allopregnanolone) for Fragile X-associated Tremor/Ataxia Syndrome
Continue
Displaying 81 - 90 of 234

Sign up for email alerts

To receive news as it is released, please sign up.

@PureTechH